New Health Affairs study shows increase in US Medicare spending linked to rising rates of chronic disease

25 February 2010

Two of the USA's leading health and fiscal policy experts this week discussed how to reign in rising health care costs in Medicare in light of a new Health Affairs study that shows rising Medicare costs in the nation's health care system are linked to the growth in several common costly chronic conditions, such as diabetes, arthritis, hypertension, and kidney disease.

Ken Thorpe, Executive Director, Emory University's Center for Entitlement Reform; Chairman, Department of Health Policy and Management, Rollins School of Public Health, Emory University; and Executive Director of the Partnership to Fight Chronic Disease, joined David Walker, President and CEO of the Peter G Peterson Foundation and former Comptroller General of the USA, to talk about the findings of the study, which he co-authored, and offer a perspective on solutions to this impending fiscal crisis.

Need to control Medicare spending

"Projected growth in Medicare spending is the single largest factor behind projections of unsustainably high deficits - and people are rightly asking: 'What can we do about it?'" said Dr Thorpe. "This study shows that in order to control Medicare spending, we must arrest the growth in chronic illnesses and related issues such as obesity. By doing so, we can do better for seniors as well as America," he added.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Pharmaceutical